Using structure-based technologies and Nobel Prize-winning expertise, Cocrystal Pharma is enrolling subjects in a Phase 1 trial for an antiviral candidate to treat pandemic and seasonal influenza A. They also plan to initiate clinical trials for COVID-19 in 2022 with orally administered and inhalation/pulmonary delivered antiviral candidates. RFS Pharma, a clinical-stage biopharmaceutical company founded by Dr. Raymond F. Schinazi, focuses on developing drugs for hepatitis infections and emerging viruses. RFS Pharma, located in suburban Atlanta, was incorporated in 2004 and in-licensed anti-hepatitis technology from Emory University in 2013. They are actively seeking promising new drugs for in-licensing.